Tonganibeia Alfred, Harries Anthony D, Merilles Onofre Edwin A, Tarataake Tekaibeti, Tiira Teatao, Kienene Takeieta
Ministry of Health and Medical Services, Kiribati (AT, TTarataake, TTiira, TK).
International Union Against Tuberculosis and Lung Disease, Paris, France and London School of Hygiene and Tropical Medicine, London, UK (ADH).
Hawaii J Med Public Health. 2018 Feb;77(2):30-34.
The Republic of Kiribati, Central Pacific, has the largest tuberculosis epidemic in the region. There is a national tuberculosis control program, which has used smear microscopy for acid-fast bacilli as the main diagnostic tool for many years. In 2015, an Xpert MTB/RIF machine was procured and became functional within the tuberculosis hospital. The aim of this cross-sectional study, using routinely collected data, was to determine the effects of introducing Xpert MTB/RIF on laboratory smear microscopy practices and the pattern of registered tuberculosis cases. Between February 2015 and January 2016, there were 220 Xpert MTB/RIF assays performed with 6.4% errors and 15% detection of one patient showed rifampicin-resistance. One year before and after introducing Xpert MTB/RIF, the number of presumptive tuberculosis patients increased by 9% from 2,138 to 2,322. There were no changes in demographic characteristics, smear-positive results, or acid-fast bacilli grade between the two periods. The number of specimens cultured for significantly declined from 638 to zero, with 76 positive MTB cultures before and none after introducing Xpert MTB/RIF. There was a significant change in the profile of registered tuberculosis cases with more children (34% versus 21%) and fewer bacteriologically-confirmed cases (29% versus 43%) - .001. Since the deployment of Xpert MTB/RIF in Kiribati, there have been a small number of assays performed and this has been associated with no adverse effects on smear microscopy, a stoppage in mycobacterial cultures, and a change in the types and categories of diagnosed tuberculosis.
位于中太平洋的基里巴斯共和国是该地区结核病疫情最为严重的国家。该国设有国家结核病控制项目,多年来一直将痰涂片显微镜检查抗酸杆菌作为主要诊断工具。2015年,采购了一台Xpert MTB/RIF检测仪,并在结核病医院投入使用。本横断面研究利用常规收集的数据,旨在确定引入Xpert MTB/RIF对实验室痰涂片显微镜检查操作以及登记结核病病例模式的影响。2015年2月至2016年1月期间,共进行了220次Xpert MTB/RIF检测,误差率为6.4%,15%的检测发现一名患者对利福平耐药。在引入Xpert MTB/RIF的前后一年,疑似结核病患者数量从2138例增加了9%,达到2322例。两个时期的人口统计学特征、涂片阳性结果或抗酸杆菌等级均无变化。培养的标本数量从638例大幅下降至零,引入Xpert MTB/RIF之前有76例结核分枝杆菌培养呈阳性,之后则无。登记结核病病例的情况发生了显著变化,儿童患者增多(34%对21%),细菌学确诊病例减少(29%对43%)——P<0.001。自Xpert MTB/RIF在基里巴斯投入使用以来,检测次数较少,且这与对痰涂片显微镜检查无不良影响、停止分枝杆菌培养以及确诊结核病的类型和类别变化有关。